VolitionRX (VolitionRX) Interest Expense : $-0.25 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is VolitionRX Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. VolitionRX's interest expense for the three months ended in Mar. 2024 was $ -0.08 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.25 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. VolitionRX's Operating Income for the three months ended in Mar. 2024 was $ -8.39 Mil. VolitionRX's Interest Expense for the three months ended in Mar. 2024 was $ -0.08 Mil. VolitionRX did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VolitionRX Interest Expense Historical Data

The historical data trend for VolitionRX's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VolitionRX Interest Expense Chart

VolitionRX Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.13

-0.16

-0.17

-0.22

VolitionRX Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.05	-0.06	-0.05	-0.06	-0.08

VolitionRX Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

VolitionRX (AMEX:VNRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VolitionRX's Interest Expense for the three months ended in Mar. 2024 was $-0.08 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-8.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $4.15 Mil.

VolitionRX's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

VolitionRX did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

VolitionRX (VolitionRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014

Website

https://www.volition.com

VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Executives

Eight Corp Ltd	10 percent owner	C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert	director, officer: SECRETARY	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds	director, officer: PRESIDENT AND CEO	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Guy Archibald Innes	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall	director	1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef	officer: Chief Scientific Officer	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Michel Gaetan	other: Manager Belgian Volition SPRL	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway	other: CEO-Singapore Volition	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer	officer: GC - Volition Diagnostics	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor	officer: Group Chief Marketing Officer	1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md	officer: Chief Medical Officer	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014